We are very pleased that one of the largest cosmetics companies and top beauty brands have chosen to test ingredients with GARDskin Dose-Response and look forward to providing data to support product safety. #cosmeticssafety #skinsensitization #invitro senzagen.com/mfn_news/senza…

We are pleased to announce a positive ESAC opinion on GARD™skin, paving the way for OECD validation. According to the positive opinion, ESAC recommends that OECD include GARD®skin on their list of internationally agreed test methods. publications.jrc.ec.europa.eu/repository/han…

It is very promising that we already get orders for our new endpoint skin irritation. senzagen.com/mfn_news/senza… #invitro #skin #genomics

Our paper on GARDskin Dose-Response has been published online in Nature Scientific Reports, providing new peer-reviewed evidence that GARD can be used as an in vitro alternative for quantitative potency assessment of skin sensitizers. nature.com/articles/s4159…

The new standard for skin sensitization ISO 10993-10 is published and now includes in vitro methods. Our GARD assay is included in the standard, can be used with saline and oil as extraction vehicles and provides human relevant results. iso.org/standard/75279… #Medicaldevices

In next week’s NURA event, our medical device expert will present the recent updates in ISO 10993-10 for In Vitro Skin Sensitization Testing. Register now to learn more: pcrm.org/ethical-scienc…

Tack alla som lyssnade på VD Peter Nählstedts presentation av SenzaGen och bolagets förvärv av VitroScreen på Investerardagen förra veckan. Missade du presentationen kan du se den här: youtube.com/watch?v=bJfy7e…

We are LIVE with an Investor Forum Online, 14:40-16:30. Schedule: 14:40 PILA PHARMA 15:00 Alzinova 15:20 Xbrane 15:40 Pause 15:50 Sprint Bioscience 16:10 SenzaGen Tune in using the link below: redeye.se/events/815891/…

Se klippet nedan – hos Redeye igår berättade VD Peter Nählstedt om den nya strategin som bolaget sjösatt under 2021, förvärvet av VitroScreen samt den senaste utvecklingen i bolaget. redeye.se/video/event-pr…

We are very proud to continue our collaboration with Research Institute for Fragrance Materials, Inc. (RIFM). RIFM’s continued trust in us affirms their appreciation of the many application areas that our GARD® technology offers. senzagen.com/mfn_news/rifm-… #invitro #Genomics

Redeye recently initiated coverage of SenzaGen, a Swedish Medtech company active in non-animal testing across several major industries. We have interviewed our analyst covering the company: $SENZA redeye.se/research/84194…

Se klippet nedan – hos Redeye AB igår berättade VD Peter Nählstedt om den starka försäljningsutvecklingen under Q1 då bolagets försäljning ökade med drygt 370 procent till 9,0 MSEK genom mycket stark organisk och förvärvsdriven tillväxt. redeye.se/video/event-pr…

Redeye endorses the news that SenzaGen has received its largest order so far, with a value of SEK 4.2m: $SENZA redeye.se/research/84704…

Redeye has interviewed SenzaGen's CEO, Peter Nählstedt. We discuss the OECD approval for GARDskin that the company received last week: $SENZA redeye.se/research/84802…

We have been selected to test substances for a new customer, a world leader in the chemicals industry. This serves as further confirmation of interest in GARD®skin’s unique capability to be used for and generate more data on difficult-to-test substances. senzagen.com/mfn_news/senza…

Redeye comments on SenzaGen's Q3 2022 sales update, with total sales of SEK9m: $SENZA redeye.se/research/85966…

Redeye endorses SenzaGen's new GARDskin order of SEK1m from a new customer within the chemical industry. Our analyst gives his initial comment: $SENZA redeye.se/research/88369…

Today at 10.40 CEO Peter Nählstedt presents at Redeye Medtech Event. Follow the live broadcast at redeye.se/events/870864/…

SenzaGen is on a growth path. Watch CEO Peter Nählstedt present the company at BioStock Life Science Summit 2023. #salesgrowth #investorpitch #ceo #biostock #invitro #genomics #machinelearning youtube.com/watch?reload=9…

Read ExxonMobil's new article on skin sensitization hazard challenges for difficult-to-test substances with conflicting or low-confidence data, where GARDskin data on UVCBs and hydrophobic substances offer insights for the integrated hazard assessment. pubmed.ncbi.nlm.nih.gov/37843019/